2025 Q2 -tulosraportti
226 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 388 | - | - | ||
| 4 612 | - | - | ||
| 165 | - | - | ||
| 6 | - | - | ||
| 269 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 t sitten1 t sittenThis will also be exciting, and could be life-changing for us: The Boston Conference (ASGCT, May 11-15, 2026): An oral presentation at a conference like ASGCT in Boston is the “blue stamp” that biotech investors and potential partners are looking for. Here are the three primary reasons why this is a defining moment for Circio: 1. The “Seal of Approval” The conference receives thousands of abstracts, but only the absolute strongest and most innovative are selected for an oral presentation. Circio’s selection means that an independent committee of world-leading experts has assessed their circVec data as among the most important breakthroughs in the field right now. For a potential partner, this removes much of the technical uncertainty. 2. Maximum exposure to "Big Pharma" In Boston, the decision makers (Business Development teams) looking for the next big technology for their portfolio will be in the audience. Traditional mRNA (as we know from COVID vaccines) has limitations due to its short lifespan in the body. When Circio stands on stage and shows data on 75 times longer stability, they are directly talking about the solution to Big Pharma's biggest problem. This is where the first steps towards licensing agreements or acquisitions are often taken. 3. Differentiation in a "Crowded" market There are many companies trying to crack the code for circular RNA. By getting speaking time at ASGCT, Circio can position itself as a frontrunner. This creates a "fear of missing out" (FOMO) among investors and partners, as they show that they are further along with their platform (circVec) than many of their competitors. What happens now? When the abstract is published on Monday, we will get the first specific details about the data they will present. This will give an indication of exactly how strong they are against their competitors.
·9 min sittenSo a Chatbot knows that it is specifically circVec that is to be their ORAL presentation as stated in the post? Not poster?
·1 t sittencircio up 1000 percent is 17 next- ·8 t sittenWe have brought in the best minds. The world's leading researchers in this field lead our development team in Stockholm. This, of course, strengthens our credibility in the industry; when we have meetings with large global companies, we see that they already know our research. It gives us a ticket and a confidence that is invaluable in this industry Your share price has been a "topic of conversation" in the market. Have you delivered a return that few others can match? This has been an incredible year. We are currently the only listed circRNA company in the world, and we are the biotech stock that has risen the most in the Nordics in the last 12 months - perhaps even globally. This shows that the market is starting to embrace the unique position we have conquered. It has also been fun for you (Investornytt ed. note ) as the only media that has actually delved into what we actually do Fact box: Billion-fold validation of circRNA The acquisition of oRNA Therapeutics for USD 2.5 billion marks a global breakthrough in circular RNA (circRNA). The mega-deal confirms that the pharmaceutical industry views this technology as the next big wave after the success of mRNA. While oRNA has now been acquired by Eli Lilly, Norwegian Circio remains the only listed circRNA company in the world. Circio has a unique technological approach and expects to reach the same maturity as regular RNA by 2027. This billion-dollar acquisition serves as a strong economic validation of the technology that Circio is developing. For investors, the agreement highlights the enormous value potential and the massive price difference between the few players in the field. Sorry for Djensen's language, "but shut up, it's going to be big!" «
·8 t sittenCalm down now, it will take up to 20 years. before that happens at a price of 120 kr. if they survive until then. I myself have shares in this.·6 t sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
226 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 t sitten1 t sittenThis will also be exciting, and could be life-changing for us: The Boston Conference (ASGCT, May 11-15, 2026): An oral presentation at a conference like ASGCT in Boston is the “blue stamp” that biotech investors and potential partners are looking for. Here are the three primary reasons why this is a defining moment for Circio: 1. The “Seal of Approval” The conference receives thousands of abstracts, but only the absolute strongest and most innovative are selected for an oral presentation. Circio’s selection means that an independent committee of world-leading experts has assessed their circVec data as among the most important breakthroughs in the field right now. For a potential partner, this removes much of the technical uncertainty. 2. Maximum exposure to "Big Pharma" In Boston, the decision makers (Business Development teams) looking for the next big technology for their portfolio will be in the audience. Traditional mRNA (as we know from COVID vaccines) has limitations due to its short lifespan in the body. When Circio stands on stage and shows data on 75 times longer stability, they are directly talking about the solution to Big Pharma's biggest problem. This is where the first steps towards licensing agreements or acquisitions are often taken. 3. Differentiation in a "Crowded" market There are many companies trying to crack the code for circular RNA. By getting speaking time at ASGCT, Circio can position itself as a frontrunner. This creates a "fear of missing out" (FOMO) among investors and partners, as they show that they are further along with their platform (circVec) than many of their competitors. What happens now? When the abstract is published on Monday, we will get the first specific details about the data they will present. This will give an indication of exactly how strong they are against their competitors.·9 min sittenSo a Chatbot knows that it is specifically circVec that is to be their ORAL presentation as stated in the post? Not poster?
- ·1 t sittencircio up 1000 percent is 17 next
- ·8 t sittenWe have brought in the best minds. The world's leading researchers in this field lead our development team in Stockholm. This, of course, strengthens our credibility in the industry; when we have meetings with large global companies, we see that they already know our research. It gives us a ticket and a confidence that is invaluable in this industry Your share price has been a "topic of conversation" in the market. Have you delivered a return that few others can match? This has been an incredible year. We are currently the only listed circRNA company in the world, and we are the biotech stock that has risen the most in the Nordics in the last 12 months - perhaps even globally. This shows that the market is starting to embrace the unique position we have conquered. It has also been fun for you (Investornytt ed. note ) as the only media that has actually delved into what we actually do Fact box: Billion-fold validation of circRNA The acquisition of oRNA Therapeutics for USD 2.5 billion marks a global breakthrough in circular RNA (circRNA). The mega-deal confirms that the pharmaceutical industry views this technology as the next big wave after the success of mRNA. While oRNA has now been acquired by Eli Lilly, Norwegian Circio remains the only listed circRNA company in the world. Circio has a unique technological approach and expects to reach the same maturity as regular RNA by 2027. This billion-dollar acquisition serves as a strong economic validation of the technology that Circio is developing. For investors, the agreement highlights the enormous value potential and the massive price difference between the few players in the field. Sorry for Djensen's language, "but shut up, it's going to be big!" «
- ·8 t sittenCalm down now, it will take up to 20 years. before that happens at a price of 120 kr. if they survive until then. I myself have shares in this.·6 t sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 388 | - | - | ||
| 4 612 | - | - | ||
| 165 | - | - | ||
| 6 | - | - | ||
| 269 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
226 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 t sitten1 t sittenThis will also be exciting, and could be life-changing for us: The Boston Conference (ASGCT, May 11-15, 2026): An oral presentation at a conference like ASGCT in Boston is the “blue stamp” that biotech investors and potential partners are looking for. Here are the three primary reasons why this is a defining moment for Circio: 1. The “Seal of Approval” The conference receives thousands of abstracts, but only the absolute strongest and most innovative are selected for an oral presentation. Circio’s selection means that an independent committee of world-leading experts has assessed their circVec data as among the most important breakthroughs in the field right now. For a potential partner, this removes much of the technical uncertainty. 2. Maximum exposure to "Big Pharma" In Boston, the decision makers (Business Development teams) looking for the next big technology for their portfolio will be in the audience. Traditional mRNA (as we know from COVID vaccines) has limitations due to its short lifespan in the body. When Circio stands on stage and shows data on 75 times longer stability, they are directly talking about the solution to Big Pharma's biggest problem. This is where the first steps towards licensing agreements or acquisitions are often taken. 3. Differentiation in a "Crowded" market There are many companies trying to crack the code for circular RNA. By getting speaking time at ASGCT, Circio can position itself as a frontrunner. This creates a "fear of missing out" (FOMO) among investors and partners, as they show that they are further along with their platform (circVec) than many of their competitors. What happens now? When the abstract is published on Monday, we will get the first specific details about the data they will present. This will give an indication of exactly how strong they are against their competitors.·9 min sittenSo a Chatbot knows that it is specifically circVec that is to be their ORAL presentation as stated in the post? Not poster?
- ·1 t sittencircio up 1000 percent is 17 next
- ·8 t sittenWe have brought in the best minds. The world's leading researchers in this field lead our development team in Stockholm. This, of course, strengthens our credibility in the industry; when we have meetings with large global companies, we see that they already know our research. It gives us a ticket and a confidence that is invaluable in this industry Your share price has been a "topic of conversation" in the market. Have you delivered a return that few others can match? This has been an incredible year. We are currently the only listed circRNA company in the world, and we are the biotech stock that has risen the most in the Nordics in the last 12 months - perhaps even globally. This shows that the market is starting to embrace the unique position we have conquered. It has also been fun for you (Investornytt ed. note ) as the only media that has actually delved into what we actually do Fact box: Billion-fold validation of circRNA The acquisition of oRNA Therapeutics for USD 2.5 billion marks a global breakthrough in circular RNA (circRNA). The mega-deal confirms that the pharmaceutical industry views this technology as the next big wave after the success of mRNA. While oRNA has now been acquired by Eli Lilly, Norwegian Circio remains the only listed circRNA company in the world. Circio has a unique technological approach and expects to reach the same maturity as regular RNA by 2027. This billion-dollar acquisition serves as a strong economic validation of the technology that Circio is developing. For investors, the agreement highlights the enormous value potential and the massive price difference between the few players in the field. Sorry for Djensen's language, "but shut up, it's going to be big!" «
- ·8 t sittenCalm down now, it will take up to 20 years. before that happens at a price of 120 kr. if they survive until then. I myself have shares in this.·6 t sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 388 | - | - | ||
| 4 612 | - | - | ||
| 165 | - | - | ||
| 6 | - | - | ||
| 269 | - | - |
Välittäjätilasto
Dataa ei löytynyt